falsefalse

Drs Leonard Gomella and Daniel Petrylak - Episode 7

Changes in NCCN Guideline: Affecting Second-Line

EP. 1: When to Image: Earlier?
EP. 2: Looking Forward: Immunotherapy and Genomics
EP. 3: MAINSAIL: Lessons Learned
EP. 4: Abiraterone: Approval and Use
EP. 5: Sequencing: Important Question With Many Answers
EP. 6: A Review of Bone-Targeted Therapies
Now Viewing
EP. 7: Changes in NCCN Guideline: Affecting Second-Line
EP. 8: Sipuleucel-T: Evidence-based Use
EP. 9: Considerations in Treatment Selection
EP. 10: Changes in NCCN Guideline: Affecting First-Line
EP. 11: Prostate Cancer: Which Guidelines

Related Content:

Drs Leonard Gomella and Daniel PetrylakProstate CancerImmuno-Oncology
Lutetium Lu 177 Vipivotide Tetraxetan Generates rPFS Improvement in PSMA+ mHSPC
First-Line Nivolumab Plus Ipilimumab Does Not Boost OS in Cisplatin-Ineligible Unresectable Urothelial Carcinoma
Indirect Comparisons Shows Relatlimab/Nivolumab Has Comparable Outcomes to Ipilimumab/Nivolumab in Advanced Melanoma
x